全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

CFTR-Related Disorder in a Patient with Sj?gren-Associated Bronchiolitis and Recurrent Pulmonary Infections: A Diagnostic Challenge

DOI: 10.4236/crcm.2026.158041, PP. 315-322

Keywords: CFTR, CFTR-Related Disorder, Bronchiectasis, Sj?gren-Associated Bronchiolitis

Full-Text   Cite this paper   Add to My Lib

Abstract:

Cystic fibrosis (CF) is an autosomal recessive disorder caused by an inherited defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It classically manifests with chronic sinopulmonary disease, pancreatic insufficiency, and infertility/subfertility. However, there are many patients whose symptoms do not align well with classic CF presentations, leading to a separate classification of many CFTR-related disorders which may have variable genotypic and phenotypic expression. This is the case of a 42-year-old female with recurrent sinopulmonary infections, autoimmune disorders, asthma, and progressive respiratory failure who had been admitted to the hospital multiple times over the course of months. Ultimately, an intermediate sweat chloride test led to further investigation which resulted in a diagnosis of a CFTR-related disorder caused by an F508del mutation. This diagnosis led to the initiation of CFTR modulator therapy, which was incorporated into a broader multidisciplinary treatment strategy that also included antimicrobial therapy, immunosuppression for Sj?gren-associated bronchiolitis, and airway-clearance measures. Although the patient experienced transient clinical stabilization, the relative contribution of each intervention could not be determined, and the patient was ultimately referred for bilateral lung transplant.

References

[1]  Endres, T.M. and Konstan, M.W. (2022) What Is Cystic Fibrosis? JAMA, 327, 191.
https://doi.org/10.1001/jama.2021.23280
[2]  Cystic Fibrosis Foundation (2025) 2025 Cystic Fibrosis Foundation Patient Registry Annual Highlights Report. Cystic Fibrosis Foundation.
[3]  Cystic Fibrosis Foundation (2009) All Fifty States to Screen Newborns for Cystic Fibrosis by 2010.
https://www.cff.org/node/766
[4]  Guo, J., Garratt, A. and Hill, A. (2022) Worldwide Rates of Diagnosis and Effective Treatment for Cystic Fibrosis. Journal of Cystic Fibrosis, 21, 456-462.
https://doi.org/10.1016/j.jcf.2022.01.009
[5]  Rowe, S.M., Miller, S. and Sorscher, E.J. (2005) Cystic Fibrosis. New England Journal of Medicine, 352, 1992-2001.
https://doi.org/10.1056/nejmra043184
[6]  Castellani, C., Duff, A.J.A., Bell, S.C., Heijerman, H.G.M., Munck, A., Ratjen, F., et al. (2018) ECFS Best Practice Guidelines: The 2018 Revision. Journal of Cystic Fibrosis, 17, 153-178.
https://doi.org/10.1016/j.jcf.2018.02.006
[7]  Farrell, P.M., White, T.B., Ren, C.L., Hempstead, S.E., Accurso, F., Derichs, N., et al. (2017) Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. The Journal of Pediatrics, 181, S4-S15.e1.
https://doi.org/10.1016/j.jpeds.2016.09.064
[8]  Ratjen, F., Bell, S.C., Rowe, S.M., Goss, C.H., Quittner, A.L. and Bush, A. (2015) Cystic Fibrosis. Nature Reviews Disease Primers, 1, Article No. 15010.
https://doi.org/10.1038/nrdp.2015.10
[9]  Boyle, M.P. (2003) Nonclassic Cystic Fibrosis and CFTR-Related Diseases. Current Opinion in Pulmonary Medicine, 9, 498-503.
https://doi.org/10.1097/00063198-200311000-00009
[10]  Sosnay, P.R., Siklosi, K.R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., et al. (2013) Defining the Disease Liability of Variants in the Cystic Fibrosis Transmembrane Conductance Regulator Gene. Nature Genetics, 45, 1160-1167.
https://doi.org/10.1038/ng.2745
[11]  De Boeck, K. and Amaral, M.D. (2016) Progress in Therapies for Cystic Fibrosis. The Lancet Respiratory Medicine, 4, 662-674.
https://doi.org/10.1016/s2213-2600(16)00023-0
[12]  Elborn, J.S. (2016) Cystic Fibrosis. The Lancet, 388, 2519-2531.
https://doi.org/10.1016/s0140-6736(16)00576-6

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133